Inotek Pharmaceuticals (NSDQ:ITEK) said last week that its glaucoma drug failed in a Phase II trial. This marks the 2nd problem for Inotek’s drug this year, after it failed in a late-stage trial comparing it to a placebo in January.
In response to the data, CEO David Southwell said in a statement that the company is assessing the future of its drug, trabodenoson, and “other strategic options.”
Get the full story at our sister site, Drug Delivery Business News.